3 Things In Biotech, June 11: Acceleron's Second Punch, Advaxis's Letdown, Seattle's New Hope [Seeking Alpha]
Advaxis, Inc. (ADXS)
Last advaxis, inc. earnings: 9/9 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.advaxis.com
Company Research
Source: Seeking Alpha
Summary Acceleron and Celgene land another big blow with their TGF blocker. Advaxis's bad news from the EMA not offset by good news for the FDA. Astellas and Seattle Genetics launch a key study for another antibody-drug conjugate. Welcome to another edition of 3 Things In Biotech You Should Learn Today, a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Acceleron and Celgene land another big blow with their TGF blocker Company: Acceleron ( XLRN ) and Celgene ( CELG ) Therapy: Lustpatercept Disease: Beta-thalassemia News: Following on recent news that lustpatercept improved survival in patients with lower-risk myelodysplastic syndrome, XLRN and CELG have announced that the BELIEVE study also met its primary study endpoint of erythroid response, defined as a reduction of transfusion dependence of at least 33% from baseline. Lustpatercept also improved the rate of 50% reduction
Show less
Read more
Impact Snapshot
Event Time:
ADXS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADXS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADXS alerts
High impacting Advaxis, Inc. news events
Weekly update
A roundup of the hottest topics
ADXS
News
- Ayala Pharmaceuticals, Inc. (NASDAQ: ADXS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Ayala Pharmaceuticals, Inc. (NASDAQ: ADXS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Ayala Pharmaceuticals, Inc. (NASDAQ: ADXS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Ayala Pharmaceuticals, Inc. (NASDAQ: ADXS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Ayala Pharmaceuticals, Inc. (NASDAQ: ADXS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
ADXS
Sec Filings
- 4/26/24 - Form 10-K/A
- 4/19/24 - Form 8-K/A
- 4/16/24 - Form 10-K
- ADXS's page on the SEC website